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Rapidly Progressing Lung Adenocarcinoma Treated with Common Bile Duct 
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Abstract 
Non-small cell lung cancer (NSCLC) is characterised by diffuse metastases, with common sites being the 
brain, liver, bones, and adrenal glands. Small bowel metastasis from NSCLC is a rare phenomenon, 
particularly in patients with an adenocarcinoma histology. We report the case of a 56-year-old lung 
adenocarcinoma patient with a duodenal metastasis diagnosed on FDG/PET-CT and confirmed on 
duodenal biopsy. Although initially asymptomatic, he subsequently presented with obstructive jaundice 
secondary to rapid local disease progression at the duodenal metastasis, requiring endoscopic 
intervention for biliary drainage. He was commenced on single agent pembrolizumab, with disease 
response on subsequent follow-up. This case highlights a rare case of gastrointestinal metastasis from 
NSCLC requiring endoscopic intervention due to rapid progression of the disease at the site of 
metastasis. 
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Abstract
Non-small cell lung cancer (NSCLC) is characterised by diffuse metastases, with common sites 
being the brain, liver, bones, and adrenal glands. Small bowel metastasis from NSCLC is a rare 
phenomenon, particularly in patients with an adenocarcinoma histology. We report the case 
of a 56-year-old lung adenocarcinoma patient with a duodenal metastasis diagnosed on FDG/
PET-CT and confirmed on duodenal biopsy. Although initially asymptomatic, he subsequent-
ly presented with obstructive jaundice secondary to rapid local disease progression at the 
duodenal metastasis, requiring endoscopic intervention for biliary drainage. He was com-
menced on single agent pembrolizumab, with disease response on subsequent follow-up. 
This case highlights a rare case of gastrointestinal metastasis from NSCLC requiring endo-
scopic intervention due to rapid progression of the disease at the site of metastasis.
© 2020 The Author(s).
Published by S. Karger AG, Basel
Introduction
Small bowel metastases originating from primary pulmonary carcinomas are un- 
common. In contrast to other metastatic sites, such as bone and brain, small bowel metastases 
are often asymptomatic, and the true incidence may be underreported. Small bowel metas-
tasis typically occurs in final stages of widespread disease and is associated with a dismal 
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prognosis, with a median survival time of 3 months seen in an autopsy study [1]. When symp-
tomatic, small bowel metastases usually present with abdominal pain, nausea, or signs of 
anaemia, and in severe cases, with small bowel obstruction or perforation, or obstructive 
jaundice secondary to extraluminal compression of the biliary tree [2–4].
We report the case of a 56-year-old male diagnosed with non-small cell lung cancer 
(NSCLC) presenting with symptomatic brain metastases who was found to have an asymp-
tomatic duodenal metastasis. He developed obstructive jaundice requiring endoscopic retro-
grade cholangiopancreatography (ERCP) and the insertion of a common bile duct (CBD) 
metal stent for symptomatic relief.
Case Report
A 56-year-old male presented to the emergency department of a regional hospital with a 
5-day history of headache and dysarthria. On examination, mild asymmetry of his lower face 
was appreciable, with the remainder of the physical examination being unremarkable apart 
from a large ventral hernia palpable on abdominal examination. He had a past medical history 
of type 2 diabetes mellitus, hypertension, hypercholesterolaemia, chronic obstructive 
pulmonary disease, gastro-oesophageal reflux disease, past hepatitis C infection, and 
depression. His surgical history was significant with a laparoscopic cholecystectomy 7 years 
prior, complicated by a bile leak and intra-abdominal sepsis requiring laparotomy and 
washout, and a subsequent large ventral hernia. He had a significant smoking history of 
approximately 50 years along with intermittent cannabis use, and a previous history of intra-
venous drug use 20 years prior to presentation.
A non-contrast brain computed tomography (CT) in the emergency department demon-
strated a large area of low density in the right frontoparietal region, with subsequent brain 
MRI revealing a rounded subcortical enhancing lesion in the right precentral gyrus with 
surrounding vasogenic oedema.
A CT of the chest, abdomen and pelvis demonstrated a  6.5-cm mass  in the left upper zone 
medially with streaky surrounding inflammatory changes in the thorax, along with several 
enlarged mediastinal and periportal lymph nodes. Staging FDG PET/CT revealed an area of 
photopenia involving the right cerebral cortex in association with a hypodensity on the 
low-dose CT scan due to the known brain metastasis. He had an intensely avid (SUVmax 10.3) 
large mass in the left upper lobe, with heterogenous distribution of tracer with a central area 
of photopenia suggestive of central necrosis, as indicated by the green arrow in Figure 1. 
There were multiple FDG-avid mediastinal, supraclavicular, and peri-portal lymph nodes, as 
well as an FDG-avid left adrenal mass. An intense area of FDG avidity in the distal duodenal 
(D2) region (SUVmax 11.8) was identified as indicated by the blue arrow in Figure 1. The 
patient had no symptoms attributable to the duodenal mass at the time of the FDG PET/CT 
scan.
The patient was commenced on regular dexamethasone 4 mg and a proton pump inhibitor 
and subsequently underwent a right frontal lobe biopsy under stereotactic guidance. Histo-
pathology of the brain metastasis demonstrated a metastatic tumour with solid sheets of 
malignant cells with atypical nuclei, eosinophilic cytoplasm, and frequent mitosis. Immuno-
histochemistry showed the tumour cells were positive for CK7 and TTF-1, consistent with a 
metastatic adenocarcinoma from a primary lung tumour. There was no targetable mutation 
detected in exon 19–21 of the epithelial growth factor receptor (EGFR) gene, and ALK, ROS-1, 
and BRAF immunohistochemistry were negative. Expression of the programmed cell death 
ligand-1 (PD-L1) was high (>95%), suggesting sensitivity to immunotherapy with checkpoint 
inhibitors.
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The patient underwent gastroscopy to investigate the FDG-avid duodenal lesion, which 
demonstrated a large semi-circumferential stenosing lesion in the second part of the 
duodenum, with ampullary orifice not visualised (Fig. 2). Endoscopic ultrasound showed 
significant peri-portal and peri-pancreatic lymphadenopathy, and a suspicious left adrenal 
gland nodule, confirming the finding of the PET scan. Biopsy of the duodenal mass demon-
strated a TTF-1-positive adenocarcinoma consistent with metastatic lung adenocarcinoma 
and concordant with the resected brain metastasis.
The patient was discharged with the intention for treatment with post-operative cranial 
radiation and immunotherapy with pembrolizumab. He subsequently presented to the emer-
gency department 12 days post initial discharge with a 4-day history of abdominal pain, dark 
urine, nausea, vomiting, and was jaundiced on clinical assessment. His liver function tests had 
become deranged in a predominately cholestatic pattern. Bilirubin was 74 μmol/L, lipase was 
654 U/L, alkaline phosphatase (ALP) 427 U/L, gamma-glutamyl transferase (GGT) 671 U/L, 
alanine aminotransferase (ALT) 279 U/L, and aspartate aminotransferase (AST) 108 U/L. 
Abdominal CT demonstrated low-grade biliary dilatation due to the rapid increase in the size 
of the duodenal lesion. Inpatient duodenoscopy revealed a large fungating mass involving the 
ampulla of the duodenum with the bulk of the mass at the biliary orifice (Fig. 3a), and ERCP 
demonstrated extrinsic compression of the CBD with extrahepatic bile duct dilatation with 
tapering to the level of the ampullary tumour involvement, requiring the insertion of a distal 
CBD fully uncovered metal stent (Fig. 3b, c).
Fig. 1. FDG PET/CT demonstrating a 
large intensely FDG-avid mass in the 
left upper lobe medially and in the  duo-
denum.
Fig. 2. Gastroscopy revealing a large semi-circumferential ste-
nosing lesion in the second part of the duodenum and uncinate 
process.
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The patient had an unremarkable admission after distal CBD metal stent insertion and 
was discharged without complications. His bilirubin normalised on discharge with corre-
sponding improvement of other liver function tests. The increase in the duodenal mass was 
deemed most likely due to disease flare at the commencement of immunotherapy, so he was 
continued on pembrolizumab. At the time of submission, he has completed cranial radio-
therapy and 36 weeks of immunotherapy with progression imaging demonstrating an ongoing 
treatment response.
Discussion
This case demonstrates the incidental finding of duodenal metastasis of NSCLC on FDG 
PET/CT and subsequent biopsy, which subsequently resulted in the patient presenting with 
biliary obstruction shortly after the diagnosis was made, requiring ERCP and biliary stent 
insertion.
Lung cancer is the leading cause of cancer death worldwide, with an estimated 1.6 million 
deaths each year, and approximately 50% of these patients have metastatic disease at the 
time of diagnosis [1, 5]. Of those diagnoses, approximately 85% have a group of histological 
subtypes known as NSCLC, of which lung adenocarcinoma and lung squamous cell carcinoma 
are the most common types [6]. NSCLC has a predominance for distal metastasis, with bone, 
brain, adrenal glands, and the kidneys being the most common sites, with the occurrence of 
metastasis to the gastrointestinal tract from lung cancer being a rare but well-recognised 
phenomenon [1, 7–9]. The incidence of gastrointestinal metastasis of primary lung malig-
nancy on autopsy studies has been published to be as high at 14%; however, the actual inci-
dence of lung cancer metastasising to the gastrointestinal tract is uncertain with approxima-
tions ranging from 0.5 to 10% depending on the method of evaluation (endoscopy, surgical 
specimen, or autopsy) [7, 10]. Although adenocarcinoma has been previously demonstrated 
to be the most frequent histological subtype of NSCLC to metastasise to the gastrointestinal 
tract, there is evidence to suggest otherwise [1, 7, 8, 11].
Metastatic disease to the gastrointestinal tract by lung cancer is deemed to be a sign of 
late-stage disease, namely due to the diffuse spread of the tumour via the haematogenous 
route, and is usually detected in those patients with a previous history of lung malignancy. In 
contrast to this, the detection of primary lung malignancy on presentation with symptoms 
attributable to gastrointestinal involvement is a rare phenomenon [11].
Fig. 3. a Duodenoscopy demonstrating a large fungating mass at the ampulla. b ERCP demonstrating extra-
hepatic bile duct dilatation with tapering to the level of the ampullary tumour. c Insertion of a distal CBD 
metal stent with free flow of contrast into the duodenum.
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ERCP-guided biliary drainage is deemed the current standard of treatment for malignant 
biliary obstruction when surgery is not an option, with a success rate approaching 95% and 
a low risk of adverse events [12–14]. In patients in which peritonitis or obstruction is 
suspected with concomitant biliary metastasis, a palliative surgical approach is recommended 
for symptom relief [15].
Conclusion
Although uncommon, this case indicates that for lesions identified in the duodenum with 
high FDG avidity, metastasis should be considered. In addition to this, in a patient with known 
duodenal metastasis, clinicians should be aware of the potential for biliary obstruction and 
obstructive pancreatitis as seen in this case, and of the potential for rapid disease progression 
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